ClinicalTrials.gg
CompletedNCT02240680Updated Jul 3, 2018Results posted

Linagliptin as Add on to Basal Insulin in the Elderly

A Phase 4 interventional study of placebo and linagliptin in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 145 sites in 17 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2018-07-03.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
21st of 67
302 · median 175
Started
2014
with 7 others
Phase 4
22 of 67
1 open now
Registered
46th of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment, is one of 8 that started in 2014, is one of 22 in phase 4, and was the 46th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To investigate the efficacy, safety, and tolerability of linagliptin 5 milligrams once a day compared to placebo as as add-on therapy for 24 weeks to stable basal insulin treatment in elderly patients, 60 years of age and older, with Type 2 Diabetes Mellitus and insufficient glycaemic control.Stable background therapy of metformin and/or alpha-glucosidase inhibitors is also allowed.

In addition, this trial will assess if linagliptin reduces the risk of hypoglycaemia when added to background basal insulin therapy. The treatment duration of this trial (24 weeks) will enable assessment of the clinically relevant endpoint of a decrease in glycosylated Haemoglobin, a well-accepted measurement of chronic glycaemic control.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must sign and date an consistent with International Conference on Harmonisation and Good Clinical Practice guidelines and local regulations prior to any evaluation and participation in the trial.
  • Male and female patients with a clinical diagnosis of Type 2 Diabetes Mellitus, at the time of Informed Consent, who are:
  • 60 years of age or older at informed consent or Screen Visit,
  • taking stable doses of basal or biosimilar basal insulin [strictly inclusive of: insulin neutral protamine Hagedorn and isophane insulin; Humalog Basal (a suspension of insulin lispro protamine); insulin degludec; insulin detemir; and insulin glargine] for at least 4 weeks prior to randomisation (Visit 3) with dose adjustments up to a maximum of plus or minus 20% of baseline being allowed,
  • may or may not be taking metformin immediate release or extended release [if the patient is taking metformin, stable dose must be maintained for at least twelve weeks without dose adjustments prior to randomisation (Visit 3)], and
  • may or may not be taking alpha-glucosidase inhibitors [acarbose, miglitol, and voglibose; if the patient is taking alpha-glucosidase inhibitors, stable dose must be maintained for at least twelve weeks without dose adjustments prior to randomisation (Visit 3)].
  • Patients must have an glycosylated of 7.0% (53 millimoles per mole) to 10.0% (86 millimoles per mole) at the first visit (Screen).
  • Patients must have a of 45 kilogram/meter squared or less at the Screen Visit.
  • In the investigator's opinion, patients must be reliable, compliant, and agree to cooperate with all planned future trial evaluations as explained in detail during the informed consent process and to be able to perform them.

Exclusion criteria

Exclusion criteria:

  • Impaired cognitive ability as supported by the Saint Louis University Mental Status Examination, additional assessment if necessary, and verified by the investigator at the Screen Visit.
  • Depressed mood as supported by a score of 10 or more on the Patient Health Questionnaire at the Screen Visit.
  • Type 1 Diabetes Mellitus as determined by past medical records and history.
  • Acute coronary syndrome (non-ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction, and/or unstable angina pectoris), stroke or within 3 months prior to Screen Visit.
  • Indication of liver disease determined during Screen and/or Run-In Period, defined by a serum level above 3 times the in any of the following: , aspartate aminotransferase, or alkaline phosphatase.
  • Bariatric, gastric bypass, and other gastrointestinal procedures or surgeries (including all types of gastric banding, restriction, and/or LapBand) with the objective of promoting weight loss within the past two years at Screen Visit.
  • Medical history of cancer (except for resected non-invasive basal or squamous cell carcinoma) and/or treatment for cancer within the last 5 years.
  • Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (malaria, babesiosis, haemolytic anaemia).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    linagliptin 5 mg

    patient to receive a tablet of linagliptin 5 mg each day

    Drug: linagliptin

  • Placebo comparator
    placebo

    patient to receive a tablet of placebo matching linagliptin 5 mg

    Drug: placebo

Interventions

  • Drugplacebo

    placebo matching linagliptin 5 mg

  • 5 mg once a day

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment.

    This outcome has measured difference between HbA1c values from baseline to 24 weeks post treatment. The term 'baseline' refers to the last observation prior to the administration of any randomised study medication. HbA1c is a form of hemoglobin, a blood pigment that carries oxygen, which is bound to glucose. The term HbA1c also refers to glycated hemoglobin. High levels of HbA1c (Normal range is less than 6%) indicate poorer control of diabetes than level in normal range.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Percentage of Patients Experiencing at Least One Hypoglycaemia Accompanied by a Prespecified Glucose Value.

    Hypoglycaemia accompanied by a prespecified glucose value is defined as any investigator reported hypoglycaemia (event or AE) with a reported blood glucose level of less than 54 milligram/deciLitre (3.0 millimole/Litre) or any investigator reported symptomatic hypoglycaemic AE with a reported blood glucose level of less or equal 70 milligram/deciLitre (3.9millimole/Litre) or any severe hypoglycaemic AE. Severe hypoglycaemia is an event that requires the assistance of another person to actively administer carbohydrates or glucagon because the patient is unable to take the substance on his or her own. The confidence intervals mentioned in measure of dispersion are exact 95% confidence interval by Clopper and Pearson. The percentage of patients with at least one hypoglycaemia accompanied by a glucose value less than 54mg/dL alone has also represented separately according American Diabetes Association definition of clinically significant hypoglycaemia.

    Time frame: 24 weeks

  2. Percentage of Patients With HbA1c<8.0%

    This is the percentage of patients with HbA1c on treatment \<8.0% after 24 weeks of treatment. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.

    Time frame: 24 weeks

  3. Percentage of Patients With HbA1c on Treatment <7.0%

    This is the percentage of patients with HbA1c on treatment \<7.0% after 24 weeks of treatment. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.

    Time frame: 24 weeks

  4. Percentage of Patients With HbA1c Lowering by at Least 0.5%.

    The percentage of patients who attained lowering of HbA1c by ≥0.5% from baseline after 24 weeks of treatment were analysed. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.

    Time frame: 24 weeks

  5. Change From Baseline in Fasting Plasma Glucose (FPG)

    This outcome has measured difference between FPG values from baseline to 24 weeks post treatment. The term 'baseline' refers to the last observation prior to the administration of any randomised study medication

    Time frame: Baseline and Week 24

07

Results

Posted Jul 3, 2018
Limitations and caveats
For patients in Japan, a local protocol amendment was introduced, and according to it the study was extended to 52 weeks for Japanese population only.

Participant flow

This was randomised, double blinded, placebo controlled, parallel study. Total 525 patients with type 2 diabetes mellitus (T2DM) and insufficient glycaemic control were screened. 302 patients were randomised into two groups. The trial was extended to 52 weeks for Japanese patients. 102 patients were identified and observed for the extended period.

Overall Study (Up to 24 Weeks)
Participant flow — Overall Study (Up to 24 Weeks)
MilestonePlacebo (Up to 24 Weeks)Linagliptin 5 Milligram (Up to 24 Weeks)Placebo (Up to 52 Weeks)Linagliptin 5 Milligram (Up to 52 Weeks)
Started15115100
Completed13614300
Not completed15800
Withdrew: Adverse event6600
Withdrew: Protocol violation4100
Withdrew: Lost to follow-up1000
Withdrew: Withdrawal by subject3100
Withdrew: Other than specified1000
Japanese Patients (Up to 52 Weeks)
Participant flow — Japanese Patients (Up to 52 Weeks)
MilestonePlacebo (Up to 24 Weeks)Linagliptin 5 Milligram (Up to 24 Weeks)Placebo (Up to 52 Weeks)Linagliptin 5 Milligram (Up to 52 Weeks)
Started005052
Completed004245
Not completed0087
Withdrew: Adverse event0067
Withdrew: Protocol violation0010
Withdrew: Withdrawal by subject0010

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment.

This outcome has measured difference between HbA1c values from baseline to 24 weeks post treatment. The term 'baseline' refers to the last observation prior to the administration of any randomised study medication. HbA1c is a form of hemoglobin, a blood pigment that carries oxygen, which is bound to glucose. The term HbA1c also refers to glycated hemoglobin. High levels of HbA1c (Normal range is less than 6%) indicate poorer control of diabetes than level in normal range.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percentage (%) of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment.
Percentage (%) of HbA1cPlacebo (Up to 24 Weeks)Linagliptin 5 Milligram (Up to 24 Weeks)
Change From Baseline in Hemoglobin A1c (HbA1c) After 24 Weeks of Treatment.-0.38 ± 0.07-1.01 ± 0.06
Statistical analysis
  • Placebo (Up to 24 Weeks) vs Linagliptin 5 Milligram (Up to 24 Weeks) · Mixed Models Analysis · p = < 0.0001 · Mean difference (final values): -0.63 · 95% CI -0.81 to -0.46Adjusted mean of all differences between HbA1c at baseline and after 24 weeks. It is based on all patients in the model (not only patients with a baseline and week 24 measurement).
SecondaryPercentage of Patients Experiencing at Least One Hypoglycaemia Accompanied by a Prespecified Glucose Value.

Hypoglycaemia accompanied by a prespecified glucose value is defined as any investigator reported hypoglycaemia (event or AE) with a reported blood glucose level of less than 54 milligram/deciLitre (3.0 millimole/Litre) or any investigator reported symptomatic hypoglycaemic AE with a reported blood glucose level of less or equal 70 milligram/deciLitre (3.9millimole/Litre) or any severe hypoglycaemic AE. Severe hypoglycaemia is an event that requires the assistance of another person to actively administer carbohydrates or glucagon because the patient is unable to take the substance on his or her own. The confidence intervals mentioned in measure of dispersion are exact 95% confidence interval by Clopper and Pearson. The percentage of patients with at least one hypoglycaemia accompanied by a glucose value less than 54mg/dL alone has also represented separately according American Diabetes Association definition of clinically significant hypoglycaemia.

Time frame:
24 weeks
Reported as:
Number · Percentage of patients (%)
Percentage of Patients Experiencing at Least One Hypoglycaemia Accompanied by a Prespecified Glucose Value.
Percentage of patients (%)Placebo (Up to 24 Weeks)Linagliptin 5 Milligram (Up to 24 Weeks)
Prespecified glucose value23.8 (17.2 to 31.5)30.9 (23.6 to 39.0)
Glucose value <54 mg/dL15.0 (9.6 to 21.8)16.8 (11.2 to 23.8)
Statistical analysis
  • Placebo (Up to 24 Weeks) vs Linagliptin 5 Milligram (Up to 24 Weeks) · Regression, Logistic · p = 0.1594 · Odds ratio (or): 1.464 · 95% CI 0.861 to 2.491The dispersion value standard error of the mean is actually standard error for odds ratio.
  • Placebo (Up to 24 Weeks) vs Linagliptin 5 Milligram (Up to 24 Weeks) · Regression, Logistic · p = 0.6720 · Odds ratio (or): 1.149 · 95% CI 0.604 to 2.188The dispersion value standard error of the mean is actually standard error for odds ratio.
SecondaryPercentage of Patients With HbA1c<8.0%

This is the percentage of patients with HbA1c on treatment \<8.0% after 24 weeks of treatment. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.

Time frame:
24 weeks
Reported as:
Number · Percentage of patients (%)
Percentage of Patients With HbA1c<8.0%
Percentage of patients (%)Placebo (Up to 24 Weeks)Linagliptin 5 Milligram (Up to 24 Weeks)
Percentage of Patients With HbA1c<8.0%40.2 (29.9 to 51.3)70.1 (59.4 to 79.5)
Statistical analysis
  • Placebo (Up to 24 Weeks) vs Linagliptin 5 Milligram (Up to 24 Weeks) · Regression, Logistic · p = < 0.0001 · Odds ratio (or): 5.018 · 95% CI 2.468 to 10.206The dispersion value standard error of the mean is actually standard error of odds ratio
SecondaryPercentage of Patients With HbA1c on Treatment <7.0%

This is the percentage of patients with HbA1c on treatment \<7.0% after 24 weeks of treatment. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.

Time frame:
24 weeks
Reported as:
Number · Percentage of Patients (%)
Percentage of Patients With HbA1c on Treatment <7.0%
Percentage of Patients (%)Placebo (Up to 24 Weeks)Linagliptin 5 Milligram (Up to 24 Weeks)
Percentage of Patients With HbA1c on Treatment <7.0%14.6 (9.3 to 21.4)37.8 (29.8 to 46.2)
Statistical analysis
  • Placebo (Up to 24 Weeks) vs Linagliptin 5 Milligram (Up to 24 Weeks) · Regression, Logistic · p = < 0.0001 · Odds ratio (or): 4.689 · 95% CI 2.485 to 8.848The dispersion value standard error of the mean is actually standard error of odds ratio
SecondaryPercentage of Patients With HbA1c Lowering by at Least 0.5%.

The percentage of patients who attained lowering of HbA1c by ≥0.5% from baseline after 24 weeks of treatment were analysed. The confidence intervals mentioned in measure of dispersion are exact 95% CI by Clopper and Pearson.

Time frame:
24 weeks
Reported as:
Number · Percentage of patients (%)
Percentage of Patients With HbA1c Lowering by at Least 0.5%.
Percentage of patients (%)Placebo (Up to 24 Weeks)Linagliptin 5 Milligram (Up to 24 Weeks)
Percentage of Patients With HbA1c Lowering by at Least 0.5%.37.4 (29.6 to 45.8)69.1 (61.0 to 76.4)
Statistical analysis
  • Placebo (Up to 24 Weeks) vs Linagliptin 5 Milligram (Up to 24 Weeks) · Regression, Logistic · p = < 0.0001 · Odds ratio (or): 3.731 · 95% CI 2.302 to 6.048The dispersion value standard error of the mean is actually standard error of odds ratio
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

This outcome has measured difference between FPG values from baseline to 24 weeks post treatment. The term 'baseline' refers to the last observation prior to the administration of any randomised study medication

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · milligram/decilitre
Change From Baseline in Fasting Plasma Glucose (FPG)
milligram/decilitrePlacebo (Up to 24 Weeks)Linagliptin 5 Milligram (Up to 24 Weeks)
Change From Baseline in Fasting Plasma Glucose (FPG)0.2 ± 3.6-11.3 ± 3.3
Statistical analysis
  • Placebo (Up to 24 Weeks) vs Linagliptin 5 Milligram (Up to 24 Weeks) · Mixed Models Analysis · p = 0.0178 · Mean difference (final values): -11.5 · 95% CI -21.0 to -2.0Adjusted mean of all differences between HbA1c at baseline and after 24 weeks. It is based on all patients in the model (not only patients with a baseline and week 24 measurement).

Adverse events

Collected over The adverse events were reported by overall population from first drug administration up to treatment period of 24 weeks, until 7 days after last drug administration. The adverse events were reported by Japanese population from first drug administration up to treatment period of 52 weeks, until 7 days after last drug administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Up to 24 Weeks)0/151 (0%)21/151 (13.9%)58/151 (38.4%)
Linagliptin 5 mg (Up to 24 Weeks)2/151 (1.3%)19/151 (12.6%)72/151 (47.7%)
Placebo (Up to 52 Weeks)0/50 (0%)7/50 (14%)19/50 (38%)
Linagliptin 5mg (Up to 52 Weeks)0/52 (0%)13/52 (25%)37/52 (71.2%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventPlacebo (Up to 24 Weeks)Linagliptin 5 mg (Up to 24 Weeks)Placebo (Up to 52 Weeks)Linagliptin 5mg (Up to 52 Weeks)
CataractEye disorders0/1511/1510/502/52
Diabetic retinopathyEye disorders0/1512/1510/502/52
CholecystitisHepatobiliary disorders1/1510/1511/500/52
CholelithiasisHepatobiliary disorders1/1510/1511/500/52
PneumoniaInfections and infestations1/1510/1511/500/52
Femoral neck fractureInjury, poisoning and procedural complications1/1510/1511/500/52
Rib fractureInjury, poisoning and procedural complications0/1510/1511/500/52
Spinal compression fractureInjury, poisoning and procedural complications0/1510/1511/500/52
HypoglycaemiaMetabolism and nutrition disorders0/1511/1511/501/52
OsteoarthritisMusculoskeletal and connective tissue disorders1/1512/1511/500/52
Most frequent other events
Most frequent other events
EventPlacebo (Up to 24 Weeks)Linagliptin 5 mg (Up to 24 Weeks)Placebo (Up to 52 Weeks)Linagliptin 5mg (Up to 52 Weeks)
HypoglycaemiaMetabolism and nutrition disorders38/15151/15114/5020/52
Viral upper respiratory tract infectionInfections and infestations8/15111/1513/5011/52
BronchitisInfections and infestations4/1517/1510/505/52
Urinary tract infectionInfections and infestations9/15110/1511/501/52
Back painMusculoskeletal and connective tissue disorders6/1515/1513/502/52
ConstipationGastrointestinal disorders1/1512/1510/503/52
Large intestine polypGastrointestinal disorders0/1512/1510/503/52
Benign prostatic hyperplasiaReproductive system and breast disorders1/1513/1510/503/52

Baseline characteristics

Treated set (TS): It includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.

Age, Continuous
Age, Continuous(Years)Placebo (Up to 24 Weeks)Linagliptin 5 Milligram (Up to 24 Weeks)Total
Mean72.5 ± 5.672.3 ± 5.172.4 ± 5.4
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Up to 24 Weeks)Linagliptin 5 Milligram (Up to 24 Weeks)Total
Female6059119
Male9192183
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo (Up to 24 Weeks)Linagliptin 5 Milligram (Up to 24 Weeks)Total
Hispanic or Latino191534
Not Hispanic or Latino132136268
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo (Up to 24 Weeks)Linagliptin 5 Milligram (Up to 24 Weeks)Total
American Indian or Alaska Native7411
Asian5252104
Native Hawaiian or Other Pacific Islander011
Black or African American10818
White8184165
More than one race123
Unknown or Not Reported000
Hemoglobin A1c (HbA1c) at baseline
Hemoglobin A1c (HbA1c) at baseline(Percentage of HbA1c (%))Placebo (Up to 24 Weeks)Linagliptin 5 Milligram (Up to 24 Weeks)Total
Mean8.1 ± 0.78.2 ± 0.88.2 ± 0.8
08

Study locations

145 sites
  • Syed Research Consultants, LLC
    Sheffield, Alabama 35660, United States
  • Precision Research Institute, LLC
    Chula Vista, California 91910, United States
  • Aurora Care Clinic, LLC
    Costa Mesa, California 92627, United States
  • Prime Care Clinical Research
    Laguna Hills, California 92653, United States
  • Torrance Clinical Research Institute Inc.
    Lomita, California 90717, United States
  • Internal Medicine of the Rockies
    Colorado Springs, Colorado 80910, United States
  • Cohen Medical Research Associates, LLC
    Delray Beach, Florida 33446, United States
  • Riverside Clinical Research
    Edgewater, Florida 32132, United States
  • Clinical Research of Hollywood
    Hollywood, Florida 33024, United States
  • East Coast Institute for Research LLC at NE FL Endo & Diabetes
    Jacksonville, Florida 32204, United States
  • Solutions Through Advanced Research, Inc.
    Jacksonville, Florida 32258, United States
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
  • Baptist Diabetes Associates, PA
    Miami, Florida 33156, United States
  • International Research Associates
    Miami, Florida 33183, United States
  • South Florida Research Solutions, LLC
    Pembroke Pines, Florida 33026, United States
  • Georgia Clinical Research, LLC
    Snellville, Georgia 30078, United States
  • Midwest Endocrinology
    Crystal Lake, Illinois 60012, United States
  • American Health Network
    Avon, Indiana 46123, United States
  • Accent Clinical Trials
    Las Vegas, Nevada 89052, United States
  • Clinical Research of South Nevada
    Las Vegas, Nevada 89121, United States
  • Manhattan Medical Research Practice PLLC
    New York, New York 10016, United States
  • Family Practice Center of Wadsworth, Inc.
    Wadsworth, Ohio 44281, United States
  • Clinical Research Associates of Central Pennsylvania
    Altoona, Pennsylvania 16602, United States
  • Fleetwood Clinical Research
    Fleetwood, Pennsylvania 19522, United States
  • Preferred Primary Care Phys
    Uniontown, Pennsylvania 15401, United States
  • TLM Medical Services, LLC
    Columbia, South Carolina 29204, United States
  • Advanced Research Associates
    Hodges, South Carolina 29653, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Arlington Family Research Center, Inc.
    Arlington, Texas 76012, United States
  • Renaissance Clinical Research and Hypertension of Texas
    Dallas, Texas 75234, United States
  • Diabetes and Thyroid Center of Fort Worth
    Fort Worth, Texas 76132, United States
  • Houston Clinical Research Associates
    Houston, Texas 77090, United States
  • Science Advancing Medicine Clinical Research Center
    San Antonio, Texas 78229, United States
  • Office of Dr. Val R. Hansen
    Bountiful, Utah 84010, United States
  • Millennium Clinical Trials LLC
    Arlington, Virginia 22203, United States
  • York Clinical Research, LLC
    Norfolk, Virginia 23510, United States
  • Rowan Research, Inc.
    Spokane, Washington 99218, United States
  • Family Medical Clinic
    Milwaukee, Wisconsin 53216, United States
  • AIM Centre
    Merewether, New South Wales 2291, Australia
  • Royal Brisbane & Women's Hospital-Endocrinology
    Herston, Queensland 4029, Australia
  • ECRU Maroondah
    East Ringwood, Victoria 3135, Australia
  • Ham - PRAC Mortelmans
    Oostham, 3945, Belgium
  • CEQUIN
    Armenia, 630004, Colombia
  • Dexa Diabetes Servicios Médicos Ltda
    Bogotá, 110221, Colombia
  • CAFAM Caja de Compensación Familiar
    Bogotá, 111211, Colombia
  • Asociacion IPS Medicos Internistas de Caldas
    Manizales, 170004, Colombia
  • Hospital Pablo Tobón Uribe
    Medellín, 050034, Colombia
  • Aalborg Sygehus Syd
    Aalborg, 9100, Denmark
  • Sydvestjyst Sygehus Esbjerg, Endokrinologisk afdeling
    Esbjerg, 6700, Denmark
  • Frederiksberg Hospital, Endokrinologisk afd.
    Frederiksberg, 2000, Denmark
  • Gentofte University Hospital
    Hellerup, 2900, Denmark
  • Kolding Sygehus
    Kolding, 6000, Denmark
  • Bispebjerg Hospital
    København NV, 2400, Denmark
  • Køge Sygehus
    Køge, 4600, Denmark
  • Roskilde Sygehus
    Roskilde, 4000, Denmark
  • Keravan terveyskeskus
    Kerava, 04200, Finland
  • Terveystalo Oulu, Diapolis
    Oulu, FI-90100, Finland
  • Lääkärikeskus Aava, Turku
    Turku, 20520, Finland
  • TYKS
    Turku, FI-20520, Finland
  • Gemeinschaftspraxis, Asslar
    Asslar, 35614, Germany
  • ikfe - Institut für klinische Forschung und Entwicklung Berlin GmbH
    Berlin, 10115, Germany
  • Diabetologische Schwerpunktpraxis, Bosenheim
    Bosenheim, 55545, Germany
  • Dünnwaldpraxis, Köln
    Koeln, 51069, Germany
  • Praxis Dr. Naudts, Rodgau
    Rodgau, 63110, Germany
  • Praxis Dr. Braun, Unterschneidheim
    Unterschneidheim, 73485, Germany
  • "Korgialeneio-Benakeio" Hellenic Red Cross Hospital
    Athens, 115 26, Greece
  • General Hospital of Athens "G. Gennimatas"
    Athens, 11527, Greece
  • Univ. Gen. Hosp. of Ioannina
    Ioannina, 45500, Greece
  • General Hospital of Attiki "KAT-EKA"
    Kifisia, 14561, Greece
  • General Hospital of Nikaia
    Nikaia, 18454, Greece
  • General Hospital of Thessaloniki "G. Papanikolaou"
    Thessaloniki, 57010, Greece
  • Connolly Hospital Blanchardstown
    Dublin, Dublin 15, Ireland
  • Daishinkai Medical Corporation Ookuma Hospital
    Aichi, Nagoya, 462-0825, Japan
  • Matsuyama Shimin Hospital
    Ehime, Matsuyama, 790-0067, Japan
  • Iryohojin Kikuchi Naika Clinic
    Gunma, Maebashi, 370-3573, Japan
  • Nakamura Digestive Organ Internal Medicine Clinic
    Hokkaido, Bibai, 072-0012, Japan
  • Iida Medical Clinic
    Hokkaido, Hakodate, 042-0942, Japan
  • Jiyugaoka Yamada Clinic
    Hokkaido, Obihiro, 080-0848, Japan
  • Shinkotoni family Clinic
    Hokkaido, Sapporo, 001-0912, Japan
  • Yoshida Memorial Hospital
    Hokkaido, Sapporo, 003-0026, Japan
  • Teine Keijinkai Clinic
    Hokkaido, Sapporo, 006-0811, Japan
  • Japan Community Health Care Organization Hokkaido Hospital
    Hokkaido, Sapporo, 062-8618, Japan
  • Itabashi Diabetic medicine and Dermatology Clinic
    Ibaraki, Koga, 306-0232, Japan
  • Nakakinen Clinic
    Ibaraki, Naka, 311-0113, Japan
  • Takai Naika Clinic
    Kanagawa, Kamakura, 247-0056, Japan
  • Kaneshiro DIAB Clinic, Kanagawa, I.M.
    Kanagawa, Sagamihara, 252-0302, Japan
  • Asahi Med. clinic, Kanagawa, I.M.
    Kanagawa, Yokohama, 221-0802, Japan
  • Ishikawa Med. Clinic, Kanagawa, I.M.
    Kanagawa, Yokohama, 241-0821, Japan
  • National Hospital Organization Yokohama Medical Center
    Kanagawa, Yokohama, 245-8575, Japan
  • Okayama Saiseikai General Hospital Outpatient Center
    Okayama, Okayama, 700-8511, Japan
  • AMC Nishi-umeda Clinic
    Osaka, Osaka, 530-0001, Japan
  • Nissay Hospital Nippon Life Saiseikai Public Interest Incorporated Foundation
    Osaka, Osaka, 550-0012, Japan
  • OCROM Clinic
    Osaka, Suita, 565-0853, Japan
  • Saga Memorial Hospital
    Saga, Saga, 849-0917, Japan
  • Asano Clinic
    Saitama, Kawagoe, 350-0851, Japan
  • Hamamatsu Rosai Hospital
    Shizuoka, Hamamatsu, 430-8525, Japan
  • Kuriyama Clinic
    Tokyo, Adachi-ku, 121-0064, Japan
  • The Institute for Adult Deseases, Asahi Life Foundation
    Tokyo, Chuo-ku, 103-0002, Japan
  • Tokyo-Eki Center-building Clinic
    Tokyo, Chuo-ku, 103-0027, Japan
  • Tokyo Center Clinic
    Tokyo, Chuo-ku, 103-0028, Japan

Showing the first 100 of 145 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Araki E, Unno Y, Tanaka Y, Sakamoto W, Miyamoto Y. Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged >/= 60 Years Treated with Basal Insulin: A Randomised Trial. Adv Ther. 2019 Oct;36(10):2697-2711. doi: 10.1007/s12325-019-01065-7. Epub 2019 Sep 3. PubMed 31482511 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Apr 2017, 30 months.

Results were first posted in Jul 2018, 1 year 2 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 30 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2014
First posted
Sep 16, 2014
StartActual
Sep 23, 2014
Primary completionActual
Apr 18, 2017
CompletionActual
Apr 25, 2017
Results first posted
Jul 3, 2018
Last update
Jul 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02240680
Responsible party
Sponsor
First posted
Sep 16, 2014
Start date
Sep 23, 2014
Primary completion
Apr 18, 2017
Completion
Apr 25, 2017
Results posted
Jul 3, 2018
Last update
Jul 3, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion